Analyst Price Targets — HNGE
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 11, 2026 6:39 pm | — | KeyBanc | $55.00 | $37.63 | TheFly | Hinge Health price target lowered to $55 from $70 at KeyBanc |
| February 11, 2026 1:35 pm | Rishi Jaluria | RBC Capital | $50.00 | $35.41 | StreetInsider | Hinge Health Inc (HNGE) PT Lowered to $50 at RBC Capital |
| February 11, 2026 1:15 pm | Elizabeth Anderson | Evercore ISI | $50.00 | $37.83 | TheFly | Hinge Health price target lowered to $50 from $65 at Evercore ISI |
| February 11, 2026 11:43 am | — | Canaccord Genuity | $53.00 | $33.05 | TheFly | Hinge Health price target lowered to $53 from $65 at Canaccord |
| February 5, 2026 4:25 pm | — | Stifel Nicolaus | $59.00 | $32.32 | TheFly | Hinge Health price target lowered to $59 from $66 at Stifel |
| January 9, 2026 11:39 am | — | Piper Sandler | $60.00 | $49.41 | TheFly | Hinge Health price target lowered to $60 from $71 at Piper Sandler |
| January 8, 2026 9:24 pm | Stan Berenshteyn | Wells Fargo | $68.00 | $49.41 | TheFly | Hinge Health initiated with an Overweight at Wells Fargo |
| January 8, 2026 12:42 pm | — | KeyBanc | $70.00 | $49.14 | TheFly | Hinge Health price target lowered to $70 from $72 at KeyBanc |
| January 5, 2026 11:45 am | — | Barclays | $60.00 | $45.56 | TheFly | Hinge Health price target lowered to $60 from $65 at Barclays |
| November 5, 2025 2:19 pm | — | Canaccord Genuity | $65.00 | $46.31 | TheFly | Hinge Health price target raised to $65 from $61 at Canaccord |
Latest News for HNGE
The cost of healthcare in the United States is on the rise in a big way. In its 2026 healthcare outlook, the Big Four accounting firm PricewaterhouseCoopers (PwC) made strong statements confirming this reality.
Shares of Hinge Health Inc. (NYSE: HNGE - Get Free Report) have earned an average recommendation of "Moderate Buy" from the nineteen analysts that are presently covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating, sixteen have given a buy rating and
The average of price targets set by Wall Street analysts indicates a potential upside of 39% in Hinge Health Inc. (HNGE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Hinge Health is using artificial intelligence to keep physical therapy costs down for employers. The company improved revenue by 51% in 2025.
Hinge Health combines robust 2025 growth (51% revenue, 31% FCF margin) with best-in-class digital MSK therapy, serving 24.6M covered lives. HNGE trades at 12–14x 2026 FCF, with management guiding 25% revenue growth but strong signals this is conservative. Defensibility against AI disruption is high due to healthcare barriers, proprietary data, hardware integration, and clinical outcomes, supporting a durable moat.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for HNGE.
U.S. House Trading
No House trades found for HNGE.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.